Brick & Kyle Associates’s GSK GSK Stock Holding History

Brick & Kyle Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-31,602	Closed	-$1.51M	–	76
2018 Q4	$1.51M	Buy	+31,602	New	+$1.56M	1.44%	25
2018 Q2	$1.6M	Sell	31,782 -1,880	-6%	-$94.7K	1.25%	28
2018 Q1	$1.64M	Sell	33,662 -121	-0.4%	-$5.63K	1.33%	25
2017 Q4	$1.5M	Hold	33,783	–	–	1.22%	27
2017 Q3	$1.71M	Sell	33,783 -240	-0.7%	-$12.2K	1.39%	27
2017 Q2	$1.83M	Hold	34,023	–	–	1.58%	25
2017 Q1	$1.79M	Hold	34,023	–	–	1.39%	26
2016 Q4	$1.64M	Hold	34,023	–	–	1.31%	30
2016 Q3	$1.83M	Buy	34,023 +2,183	+7%	+$120K	1.47%	26
2016 Q2	$1.73M	Buy	31,840 +160	+0.5%	+$8.43K	1.41%	27
2016 Q1	$1.61M	Hold	31,680	–	–	1.39%	30
2015 Q4	$1.6M	Sell	31,680 -845	-3%	-$43.1K	1.41%	29
2015 Q3	$1.56M	Buy	32,525 +500	+2%	+$26K	1.47%	25
2015 Q2	$1.67M	Sell	32,025 -80	-0.2%	-$4.5K	1.4%	25
2015 Q1	$1.85M	Sell	32,105 -320	-1%	-$18.3K	1.59%	20
2014 Q4	$1.73M	Buy	+32,425	New	+$1.81M	1.5%	24

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Brick & Kyle Associates's GSK Position: Q1 2019 in Review

Brick & Kyle Associates sold out of GSK (GSK) in Q1 2019, closing a stake of 31,602 shares — an estimated $1.51M sold.

Brick & Kyle Associates first reported a position in GSK in Q4 2014 and held it in 16 quarters. The position peaked at $1.85M in Q1 2015. 848 funds tracked by Wall St. Rank hold GSK as of Q1 2019.

Brick & Kyle Associates reported no remaining GSK position as of Q1 2019 after selling out during the quarter.
Brick & Kyle Associates sold 31,602 GSK shares in Q1 2019, an estimated $1.51M.
Brick & Kyle Associates first reported a position in GSK in Q4 2014 and held it in 16 quarters.
Brick & Kyle Associates's GSK position peaked at $1.85M in Q1 2015.
848 funds tracked by Wall St. Rank held GSK as of Q1 2019.

Based on Brick & Kyle Associates's 13F filing for Q1 2019, filed 14 Jun 2019.